Skip to main content
OpenTrials
Completed

NCT Number: NCT02384876

Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age.

The incidence of arterial hypotension under general anesthesia using sevoflurane is particularly high in newborns and infants up to 6 months of age. A decrease of 20% of the initial mean blood pressure (mBP) is the definition of significant arterial hypotension in adults and children. In adults, intraoperative arterial hypotension is associated with an increase of intraoperative mortality and a certain neurological morbidity. In infants under 6 months of age, neurological disorders have been reported following general anesthesia. Neurotoxicity of hypnotics is often incriminated as should be the episodes of arterial hypotension.

Current management of hypotension uses vascular filling with crystalloids and vasopressive amines in second intention. Dopamine is the most frequently used amine. Ephedrine can also be used. Ephedrine is particularly interesting because of its action on both α and β receptors and its mode of administration: one dose and peripheral access.

Only one study is available in children from birth to adulthood; it demonstrates a lower hemodynamic response in infants than in adults, when administered a low dose of Ephedrine (0.1 to 0.2 mg/kg). A recent retrospective cohort suggests an under efficacy of low doses and the use of higher doses than those recommended.

The primary objective is to determine the optimal dose of ephedrine (dose of ephedrine associated with a difference of proportion of newborns/infants in therapeutic success of 55%) compare to the reference dose of 0.1mg/kg as a first line treatment of intraoperative arterial hypotension.

Secondary objectives:

* Return to a mBP superior to 38mmHg post Ephedrine administration. * To assess occurrence of hypoxemic events during anesthesia. * To assess tolerance of ephedrine. One hundred and twenty newborn and infants up to 6 months of age will be recruited in 3 sites of the Rhone Alpes Auvergne area over 24 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intraoperative Arterial Hypotension Infant, Newborn

Age range

Up to 6 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hôpital d'Estaing, Clermont-Ferrand, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newborns or infants < 6 months of age,
  • boys and girls,
  • premature or not,
  • requiring general anesthesia induced by sevoflurane
  • who presents during anesthesia a decrease of blood pressure superior to 20% of the basal mBP (measured prior to surgery) despite of vascular filling with sodium chloride 0.9% (10mL/kg during 10 min).
  • Written, informed consent obtained from the 2 parents

Exclusion criteria

  • Allergy to Ephedrine.
  • Emergency surgery.
  • Patient having previously received other vasopressive amines.
  • Use of other indirect sympathomimetic drug such as phenylpropanolamine, phenylephrine, pseudoephedrine and methylphenidate.
  • Premedication with clonidine
  • Congenital heart disease
  • IV-induced anesthesia.

Treatment and study plan

Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG

Drug

Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.

Drug

Primary outcomes

  1. Therapeutic success is defined as a mBP superior to 55% of the basal mBP (prior to anesthesia) within 10 minutes post Ephedrine administration

    Time frame: Continuous monitoring within 10 minutes post-administration

Secondary outcomes

  1. Return to a mBP superior to 38mmHg within 10 minutes post Ephedrine administration

    Time frame: Continuous monitoring within 10 minutes post-administration

  2. Variations of O2 saturation in cerebral tissue (number of desaturations, evolution under treatment) using a Near Infrared Spectroscopy (NIRS) technology

    Time frame: Continuous monitoring within 10 minutes post-administration

  3. Tolerance of Ephedrine: occurrence of serious adverse events

    Time frame: During 3 days post-administration

    Clinical examination focusing specifically on heart rate and hypertension

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age. A Randomized, Controlled, Open-label, Dose Escalation Study.

Acronym: EPHEDRINE

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Mar 10, 2015
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.